Fundz

Janux Therapeutics, Inc. reported raising $125 Million in an initial SEC Form D filing, from an offering of $125 Million

PUBLIC · JANXApr 30, 2021

Amount Raised

$125 Million

$125 Million sold, per SEC Form D (first sale Apr 30, 2021)

Round Type

Venture

San DiegoBiotechnologyTherapeutics

Who to call at Janux Therapeutics, and when

A new round usually means Janux Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Janux Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Janux Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Janux Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Janux Therapeutics

Location

San Diego, California, United States

About

Janux is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Janux’s proprietary technology enabled the development of two distinct bispecific platforms: TRACTr and TRACIr. The goal of both platforms is to provide cancer patients with safe and effective therapeutics that direct and guide their immune system to eradicate tumors while minimizing safety concerns. Janux is currently developing a broad pipeline of TRACTr and TRACIr therapeutics directed at several targets to treat solid tumors. Janux has two TRACTr therapeutic candidates in clinical trials, the first targeting PSMA is in development for prostate cancer, and the second targeting EGFR is being developed for colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Janux Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsNina K., Lab manager hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Janux Therapeutics's next move

See what Strategic adds

Janux Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.